advertisement
Abstract #8997 Published in IGR 5-2
A clinical study of the neuroprotection effect of erigeron breviscapus hand mazz on glaucomatous patient eyes
Ye C; Jiang YChinese Ophthalmic Research 2003; 21: 307-311
OBJECTIVE: To evaluate the neuroprotection effect of erigeron breviscapus (vant) hand mazz (EBHM) on patients with intraocular pressure (IOP) controlled glaucoma. METHODS: A prospective, randomized, double masked, placebo control clinical trial was conducted. Forty-five patients (eyes) with moderate and late glaucoma were enrolled and randomly assigned to the EBHM group and age-matched placebo control group. Follow-up visits were scheduled every month. The following tests were performed at the beginning and at every visit: IOP, corrected visual acuity, C/D ratio, visual field (Twinfield, OCULUS, Germany), heart rate and blood pressure. RESULTS: IOP was 14.17 ± 2.50 and 14.52 ± 1.94 mmHg for EBHM and control groups, respectively (p = 0.598) for six months. After six months, mean sensitivity (MS) increased 1.42 dB in EBHM group, and dropped 0.95 dB in control group (p = 0.000). The rate of visual field improvement in EBHM and control groups was 56.52 and 4.55%, respectively (p = 0.001). No systemic side-effects related to EBHM were found. CONCLUSIONS: EBHM could improve visual field in patients with IOP controlled glaucoma. When IOP was below 15 mmHg, EBHM has less risk for the glaucomatous optic neuropathy and greater effect on reducing the visual field defects. EBHM therapy shows favorable effect on patients with moderate and late glaucoma. LA: Chinese
Dr. C. Ye, Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha 410011, China. ye ch2000@yahoo.com
Classification:
11.8 Neuroprotection (Part of: 11 Medical treatment)
